<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
      <PMID Version="1">35370008</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1095-6859</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>165</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Gynecologic oncology</Title>
          <ISOAbbreviation>Gynecol Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma.</ArticleTitle>
        <Pagination>
          <StartPage>577</StartPage>
          <EndPage>584</EndPage>
          <MedlinePgn>577-584</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ygyno.2022.03.016</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0090-8258(22)00198-6</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Clear cell and endometrioid ovarian carcinomas (OCC and OEC, respectively) have a presumed origin in endometriosis and share molecular alterations with each other and with their endometrial counterparts. The Cancer Genome Atlas (TCGA)-based molecular classification stratifies endometrial carcinomas into four categories: POLE mutated (POLEmut), mismatch repair deficient (MMRd), p53 abnormal (p53abn) and no specific molecular profile (NSMP) with divergent prognoses. The subsequent studies are indicative that this TCGA classification has some value in OEC, but the knowledge related to OCC is limited.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Endometrial carcinoma molecular classification was evaluated and compared in a large series of OCCs (n = 115) and OECs (n = 158). POLE mutation analysis and tissue microarray-based immunohistochemistry for mismatch repair and p53 proteins were performed.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The distribution to the molecular groups was as follows: POLEmut 0.9%/3.2%, MMRd 3.5%/6.3%, p53abn 20%/30%, and NSMP 76%/60% in OCCs/OECs, respectively. The proportion of NSMP tumors was the largest in both histological types and significantly higher in OCC than OEC (p = 0.009). The molecular classification correlated significantly with DSS in both OCCs and OECs (p &lt; 0.001 and p = 0.009, respectively), and with DFS in OCCs (p = 0.001). POLEmut and MMRd OCCs carried excellent prognosis, whereas MMRd OECs presented with poorer outcome. The p53abn group was associated with the poorest prognosis in both tumor types, particularly emphasized in OCCs.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">TCGA molecular classification associated with patient outcome in both histotypes, and the difference in prognosis between the molecular groups was even more marked in OCC. The large amount of NSMP tumors highlights the need for further studies.</AbstractText>
          <CopyrightInformation>Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Similä-Maarala</LastName>
            <ForeName>Jonna</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, Haartmaninkatu 3, PO Box 400, 00290 HUS, Helsinki, Finland. Electronic address: jonna.simila-maarala@hus.fi.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Soovares</LastName>
            <ForeName>Piret</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 2, PO Box 140, 00029 HUS, Helsinki, Finland. Electronic address: piret.soovares@hus.fi.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pasanen</LastName>
            <ForeName>Annukka</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, Haartmaninkatu 3, PO Box 400, 00290 HUS, Helsinki, Finland. Electronic address: annukka.pasanen@hus.fi.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ahvenainen</LastName>
            <ForeName>Terhi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical and Clinical Genetics and Applied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland, University of Helsinki, Haartmaninkatu 8, PO Box 63, 00014, Finland. Electronic address: terhi.ahvenainen@helsinki.fi.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vahteristo</LastName>
            <ForeName>Pia</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical and Clinical Genetics and Applied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland, University of Helsinki, Haartmaninkatu 8, PO Box 63, 00014, Finland. Electronic address: pia.vahteristo@helsinki.fi.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bützow</LastName>
            <ForeName>Ralf</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, Haartmaninkatu 3, PO Box 400, 00290 HUS, Helsinki, Finland. Electronic address: ralf.butzow@hus.fi.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lassus</LastName>
            <ForeName>Heini</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Gynecologic Oncology, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 2, PO Box 140, 00029 HUS, Helsinki, Finland. Electronic address: heini.lassus@hus.fi.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>31</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Gynecol Oncol</MedlineTA>
        <NlmUniqueID>0365304</NlmUniqueID>
        <ISSNLinking>0090-8258</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Clear cell</Keyword>
        <Keyword MajorTopicYN="N">Endometrioid</Keyword>
        <Keyword MajorTopicYN="N">MMR</Keyword>
        <Keyword MajorTopicYN="N">Ovarian carcinoma</Keyword>
        <Keyword MajorTopicYN="N">POLE</Keyword>
        <Keyword MajorTopicYN="N">p53</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest All authors declare no conflict of interest related to this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>4</Day>
          <Hour>5</Hour>
          <Minute>25</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35370008</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ygyno.2022.03.016</ArticleId>
        <ArticleId IdType="pii">S0090-8258(22)00198-6</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
